Accessibility Menu
 
Tenaya Therapeutics logo

Tenaya Therapeutics

(NASDAQ) TNYA

Current Price$0.90
Market Cap$184.10M
Since IPO (2021)-94%
5 YearN/A
1 Year+89%
1 Month+27%

Tenaya Therapeutics Financials at a Glance

Market Cap

$184.10M

Revenue (TTM)

$225.00K

Net Income (TTM)

$83.00M

EPS (TTM)

$-0.47

P/E Ratio

-1.80

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.90

Volume

2,673,815.652

Open

$0.86

Previous Close

$0.85

Daily Range

$0.85 - $0.93

52-Week Range

$0.36 - $2.35

TNYA: Motley Fool Moneyball Superscore

43

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tenaya Therapeutics

Industry

Biotechnology

Employees

70

CEO

Faraz Ali, MBA

Headquarters

South San Francisco, CA 94080, US

TNYA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

-382%

Net Income Margin

-369%

Return on Equity

-74%

Return on Capital

-73%

Return on Assets

-61%

Earnings Yield

-55.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$184.10M

Shares Outstanding

217.00M

Volume

2.67M

Avg. Volume

4.22M

Financials (TTM)

Gross Profit

$8.44M

Operating Income

$93.33M

EBITDA

$84.89M

Operating Cash Flow

$68.26M

Capital Expenditure

$618.00K

Free Cash Flow

$68.88M

Cash & ST Invst.

$100.55M

Total Debt

$10.83M

Tenaya Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$225.00K

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$184.10M

N/A

Market Cap/Employee

$1.90M

N/A

Employees

97

N/A

Net Income

$19.27M

+28.3%

EBITDA

$20.07M

+19.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$70.77M

-5.9%

Accounts Receivable

$10.63M

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.00M

-30.8%

Short Term Debt

$3.12M

+11.5%

Return on Assets

-61.45%

N/A

Return on Invested Capital

-72.58%

N/A

Free Cash Flow

$19.25M

+18.1%

Operating Cash Flow

$19.23M

+16.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRBUCaribou Biosciences, Inc.
$1.93+2.39%
IMRXImmuneering Corporation
$5.17-0.86%
HUMAHumacyte, Inc.
$1.03-4.17%
PYXSPyxis Oncology, Inc.
$2.57+13.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.45+0.07%
RXTRackspace Technology
$5.02+0.43%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.59-0.05%
EOSEEos Energy Enterprises
$7.59+0.19%

Questions About TNYA

What is the current price of Tenaya Therapeutics?

Tenaya Therapeutics is trading at $0.89 per share.

What is the 52-week range for Tenaya Therapeutics?

Over the past 52 weeks, Tenaya Therapeutics has traded between $0.36 and $2.35.

How much debt does Tenaya Therapeutics have?

As of the most recent reporting period, Tenaya Therapeutics reported total debt of $10.12M.

How much cash does Tenaya Therapeutics have on hand?

Tenaya Therapeutics reported $80.89M in cash and cash equivalents in its most recent financial results.

What is Tenaya Therapeutics’s dividend yield?

Tenaya Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.